OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
hiPSCs in cardio-oncology: deciphering the genomics
Emily Pinheiro, K. Ashley Fetterman, Paul W. Burridge
Cardiovascular Research (2019) Vol. 115, Iss. 5, pp. 935-948
Open Access | Times Cited: 24
Emily Pinheiro, K. Ashley Fetterman, Paul W. Burridge
Cardiovascular Research (2019) Vol. 115, Iss. 5, pp. 935-948
Open Access | Times Cited: 24
Showing 24 citing articles:
Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician
Irving E. Perez, Sara Taveras Alam, Gabriel A. Hernandez, et al.
Clinical Medicine Insights Cardiology (2019) Vol. 13
Open Access | Times Cited: 151
Irving E. Perez, Sara Taveras Alam, Gabriel A. Hernandez, et al.
Clinical Medicine Insights Cardiology (2019) Vol. 13
Open Access | Times Cited: 151
Preventing and Treating Anthracycline Cardiotoxicity: New Insights
Konrad Teodor Sawicki, Valentina Sala, Lorenzo Prever, et al.
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 309-332
Closed Access | Times Cited: 131
Konrad Teodor Sawicki, Valentina Sala, Lorenzo Prever, et al.
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 309-332
Closed Access | Times Cited: 131
Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?
Alessandra Murabito, Emilio Hirsch, Alessandra Ghigo
Frontiers in Cardiovascular Medicine (2020) Vol. 7
Open Access | Times Cited: 81
Alessandra Murabito, Emilio Hirsch, Alessandra Ghigo
Frontiers in Cardiovascular Medicine (2020) Vol. 7
Open Access | Times Cited: 81
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Ulf Landmesser, Wolfgang Poller, Sotirios Tsimikas, et al.
European Heart Journal (2020) Vol. 41, Iss. 40, pp. 3884-3899
Open Access | Times Cited: 79
Ulf Landmesser, Wolfgang Poller, Sotirios Tsimikas, et al.
European Heart Journal (2020) Vol. 41, Iss. 40, pp. 3884-3899
Open Access | Times Cited: 79
Signaling Pathways Underlying Anthracycline Cardiotoxicity
Valentina Sala, Angela Della Sala, Emilio Hirsch, et al.
Antioxidants and Redox Signaling (2020) Vol. 32, Iss. 15, pp. 1098-1114
Closed Access | Times Cited: 50
Valentina Sala, Angela Della Sala, Emilio Hirsch, et al.
Antioxidants and Redox Signaling (2020) Vol. 32, Iss. 15, pp. 1098-1114
Closed Access | Times Cited: 50
Anthracycline Toxicity: Light at the End of the Tunnel?
Romina B. Cejas, Kateryna Petrykey, Yadav Sapkota, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 115-134
Open Access | Times Cited: 15
Romina B. Cejas, Kateryna Petrykey, Yadav Sapkota, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 115-134
Open Access | Times Cited: 15
Update on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA ) of the ESC , the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, et al.
European Journal of Heart Failure (2025)
Open Access
Alessandra Ghigo, Pietro Ameri, Aarti Asnani, et al.
European Journal of Heart Failure (2025)
Open Access
Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity
Mohit Kumar, Chellappagounder Thangavel, Richard C. Becker, et al.
Cancers (2020) Vol. 13, Iss. 1, pp. 86-86
Open Access | Times Cited: 31
Mohit Kumar, Chellappagounder Thangavel, Richard C. Becker, et al.
Cancers (2020) Vol. 13, Iss. 1, pp. 86-86
Open Access | Times Cited: 31
Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
Moyun Li, Peng Li-ming, Xiaoping Chen
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 17
Moyun Li, Peng Li-ming, Xiaoping Chen
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 17
Toxicity testing in the era of induced pluripotent stem cells: A perspective regarding the use of patient-specific induced pluripotent stem cell–derived cardiomyocytes for cardiac safety evaluation
Li Pang
Current Opinion in Toxicology (2020) Vol. 23-24, pp. 50-55
Open Access | Times Cited: 27
Li Pang
Current Opinion in Toxicology (2020) Vol. 23-24, pp. 50-55
Open Access | Times Cited: 27
Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods
Ziyu Kuang, Miao Kong, Ningzhe Yan, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 5, pp. 679-701
Open Access | Times Cited: 2
Ziyu Kuang, Miao Kong, Ningzhe Yan, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 5, pp. 679-701
Open Access | Times Cited: 2
Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need
Javid J. Moslehi, Keigi Fujiwara, Tomasz J. Guzik
Cardiovascular Research (2019) Vol. 115, Iss. 5, pp. 819-823
Closed Access | Times Cited: 21
Javid J. Moslehi, Keigi Fujiwara, Tomasz J. Guzik
Cardiovascular Research (2019) Vol. 115, Iss. 5, pp. 819-823
Closed Access | Times Cited: 21
Anthracycline-Induced Cardiomyopathy in Cancer Survivors: Management and Long-Term Implications
Seyed Abolfazl Mohsenizadeh, Mohsen Rajaeinejad, Mehran Khoshfetrat, et al.
Advances in experimental medicine and biology (2024)
Closed Access | Times Cited: 2
Seyed Abolfazl Mohsenizadeh, Mohsen Rajaeinejad, Mehran Khoshfetrat, et al.
Advances in experimental medicine and biology (2024)
Closed Access | Times Cited: 2
Cell Transdifferentiation and Reprogramming in Disease Modeling: Insights into the Neuronal and Cardiac Disease Models and Current Translational Strategies
Rajkumar Singh Kalra, Jaspreet Kaur Dhanjal, Mriganko Das, et al.
Cells (2021) Vol. 10, Iss. 10, pp. 2558-2558
Open Access | Times Cited: 12
Rajkumar Singh Kalra, Jaspreet Kaur Dhanjal, Mriganko Das, et al.
Cells (2021) Vol. 10, Iss. 10, pp. 2558-2558
Open Access | Times Cited: 12
Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population
Aleksandra Grela-Wojewoda, Mirosława Püsküllüoğlu, Beata Sas-Korczyńska, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3353-3353
Open Access | Times Cited: 8
Aleksandra Grela-Wojewoda, Mirosława Püsküllüoğlu, Beata Sas-Korczyńska, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3353-3353
Open Access | Times Cited: 8
Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools
Li Pang, Zhichao Liu, Wei Feng, et al.
Archives of Toxicology (2020) Vol. 95, Iss. 3, pp. 791-805
Closed Access | Times Cited: 8
Li Pang, Zhichao Liu, Wei Feng, et al.
Archives of Toxicology (2020) Vol. 95, Iss. 3, pp. 791-805
Closed Access | Times Cited: 8
Proteomic Profiling Reveals Roles of Stress Response, Ca2+ Transient Dysregulation, and Novel Signaling Pathways in Alcohol‐Induced Cardiotoxicity
Rui Liu, Fangxu Sun, Parvin Forghani, et al.
Alcoholism Clinical and Experimental Research (2020) Vol. 44, Iss. 11, pp. 2187-2199
Open Access | Times Cited: 7
Rui Liu, Fangxu Sun, Parvin Forghani, et al.
Alcoholism Clinical and Experimental Research (2020) Vol. 44, Iss. 11, pp. 2187-2199
Open Access | Times Cited: 7
Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury
Juan Zhen, Haitao Yu, Honglei Ji, et al.
Life Sciences (2019) Vol. 239, pp. 117070-117070
Closed Access | Times Cited: 5
Juan Zhen, Haitao Yu, Honglei Ji, et al.
Life Sciences (2019) Vol. 239, pp. 117070-117070
Closed Access | Times Cited: 5
Prevention of adverse drug effects: a pharmacogenomic approach
Erika N. Scott, Jafar S. Hasbullah, Bruce Carleton, et al.
Current Opinion in Pediatrics (2020) Vol. 32, Iss. 5, pp. 646-653
Closed Access | Times Cited: 4
Erika N. Scott, Jafar S. Hasbullah, Bruce Carleton, et al.
Current Opinion in Pediatrics (2020) Vol. 32, Iss. 5, pp. 646-653
Closed Access | Times Cited: 4
Molecular biomarkers in cardio‐oncology: Where we stand and where we are heading
Panagiotis Vasileiou, Gerasimos Siasos, Vassilis G. Gorgoulis
BioEssays (2022) Vol. 44, Iss. 6
Closed Access | Times Cited: 2
Panagiotis Vasileiou, Gerasimos Siasos, Vassilis G. Gorgoulis
BioEssays (2022) Vol. 44, Iss. 6
Closed Access | Times Cited: 2
Cardiotoxicity Monitoring in Patients With Cancer: Focus on Safety and Clinical Relevance
Giselle Alexandra Suero-Abreu, Sarju Ganatra, Tomas G. Neilan
JCO Oncology Practice (2021) Vol. 17, Iss. 5, pp. 237-239
Open Access | Times Cited: 2
Giselle Alexandra Suero-Abreu, Sarju Ganatra, Tomas G. Neilan
JCO Oncology Practice (2021) Vol. 17, Iss. 5, pp. 237-239
Open Access | Times Cited: 2
Left Ventricular Systolic Function Has Strong Independent Genetic Background from Diastolic Function: A Classical Twin Study
Andrea Molnár, Márton Kolossváry, Bálint Károly Lakatos, et al.
Medicina (2021) Vol. 57, Iss. 9, pp. 935-935
Open Access | Times Cited: 1
Andrea Molnár, Márton Kolossváry, Bálint Károly Lakatos, et al.
Medicina (2021) Vol. 57, Iss. 9, pp. 935-935
Open Access | Times Cited: 1
hiPSCs for population genetics
Zhifen Chen, Shi Su, Chad A. Cowan
Elsevier eBooks (2022), pp. 19-44
Closed Access
Zhifen Chen, Shi Su, Chad A. Cowan
Elsevier eBooks (2022), pp. 19-44
Closed Access
Modeling the cardiovascular toxicities of anticancer therapies in the era of precision medicine
Logan Dunkenberger, Ioannis Karakikes
Elsevier eBooks (2021), pp. 1-22
Closed Access
Logan Dunkenberger, Ioannis Karakikes
Elsevier eBooks (2021), pp. 1-22
Closed Access
